Tranzyme Pharma To Present At BIO Investor Forum On October 10, 2012

RESEARCH TRIANGLE PARK, N.C., Oct. 3, 2012 (GLOBE NEWSWIRE) -- Tranzyme Pharma (Nasdaq:TZYM), today announced that Vipin K. Garg, Ph.D., President and CEO, will present at the 11 ^th Annual BIO Investor Forum taking place at the Palace Hotel in San Francisco, CA October 9-10, 2012. Tranzyme's presentation is scheduled for Wednesday, October 10 ^th at 11:00 am PT in the Sea Cliff Presentation Room.

A live audio webcast of the presentation will be available in the "Investors" section of the Tranzyme Pharma website, www.tranzyme.com .

About Tranzyme Pharma

Tranzyme Pharma is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel, mechanism-based therapeutics for the treatment of upper gastrointestinal (GI) motility disorders. While approximately 40 percent of people in the U.S. are affected by these persistent and recurring conditions which disrupt the normal movement of food throughout the GI tract, there are a limited number of safe and effective treatment options. Tranzyme is developing TZP-102, an oral ghrelin agonist for treating the symptoms associated with chronic upper GI motility disorders. Enrollment is complete in a multinational Phase 2b trial evaluating TZP-102 given once daily in diabetic patients with gastroparesis; top-line data are expected by year-end 2012. Tranzyme has initiated a second Phase 2b trial (DIGEST) evaluating TZP-102 given prior to meals in diabetic patients with gastroparesis; top-line data are expected in the first half of 2013. By leveraging its proprietary drug discovery technology, MATCH™, Tranzyme is committed to pursuing first-in-class medicines to address areas of significant unmet medical needs.

Further information about Tranzyme Pharma can be found on the Company's web site at www.tranzyme.com .

CONTACT: Corporate Inquiries:
         Susan Sharpe
         Director, Corporate Communications
         [phone]
         [e-mail]
         
         Investor Inquiries:
         David Carey
         Lazar Partners, Ltd.
         [phone]
         [e-mail]